18. Patents on Life Forms

The patenting of life forms, including genes, organisms, and genetically modified animals, raises significant ethical and practical concerns. Critics argue that such patents can lead to monopolies, restricting access to essential medicines and hindering further research. Additionally, the commodification of life forms may undermine the intrinsic value of biodiversity and indigenous knowledge. The Indigenous Peoples Council on Biocolonialism (IPCB) has been particularly vocal, advocating for the protection of indigenous genetic resources and opposing the patenting of life forms. (en.wikipedia.org) In response to these concerns, some biotech companies are adopting more ethical practices. For instance, Variant Bio, a Seattle-based biotech firm, collaborates with indigenous communities to develop drugs for obesity and diabetes, sharing revenues and avoiding patenting genes. (bioethics.com) The U.S. Patent and Trademark Office (USPTO) has guidelines regarding the patentability of life forms, emphasizing that naturally occurring products are not patentable, while genetically modified organisms may be, provided they meet specific criteria. (iatp.org) The debate over patenting life forms continues, balancing the potential for scientific advancement with ethical considerations about ownership, access, and the protection of indigenous rights.